155 related articles for article (PubMed ID: 34782922)
1. Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus.
Wohlfarth D; Frehtman V; Müller M; Vogel M; Phan LMP; Brunecker A; Leuchs B
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9113-9124. PubMed ID: 34782922
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
3. Development of an HSV-1 production process involving serum-reduced culturing and bead-to-bead transfer.
Wang H; Hu X; Zhang M; Yang L; Xu Y; Gu X; Jiang J; Hu W
Appl Microbiol Biotechnol; 2024 Jun; 108(1):383. PubMed ID: 38896301
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.
Geiss C; Kis Z; Leuchs B; Frank-Stöhr M; Schlehofer JR; Rommelaere J; Dinsart C; Lacroix J
Viruses; 2017 Oct; 9(10):. PubMed ID: 29039746
[TBL] [Abstract][Full Text] [Related]
5. Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application.
Frehtman V; Wohlfarth D; Müller M; Krebs O; Leuchs B
Appl Microbiol Biotechnol; 2023 Aug; 107(15):4777-4787. PubMed ID: 37209160
[TBL] [Abstract][Full Text] [Related]
6. Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells.
Liu S; Ruban L; Wang Y; Zhou Y; Nesbeth DN
Heliyon; 2017 Feb; 3(2):e00238. PubMed ID: 28203643
[TBL] [Abstract][Full Text] [Related]
7. Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.
Lesch HP; Heikkilä KM; Lipponen EM; Valonen P; Müller A; Räsänen E; Tuunanen T; Hassinen MM; Parker N; Karhinen M; Shaw R; Ylä-Herttuala S
Hum Gene Ther; 2015 Aug; 26(8):560-71. PubMed ID: 26176404
[TBL] [Abstract][Full Text] [Related]
8. Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.
Göbel S; Jaén KE; Dorn M; Neumeyer V; Jordan I; Sandig V; Reichl U; Altomonte J; Genzel Y
Biotechnol Bioeng; 2023 Sep; 120(9):2639-2657. PubMed ID: 36779302
[TBL] [Abstract][Full Text] [Related]
9. Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.
Josupeit R; Bender S; Kern S; Leuchs B; Hielscher T; Herold-Mende C; Schlehofer JR; Dinsart C; Witt O; Rommelaere J; Lacroix J
Viruses; 2016 May; 8(5):. PubMed ID: 27213425
[TBL] [Abstract][Full Text] [Related]
10. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
11. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
[TBL] [Abstract][Full Text] [Related]
12. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
Ferreira T; Kulkarni A; Bretscher C; Nazarov PV; Hossain JA; Ystaas LAR; Miletic H; Röth R; Niesler B; Marchini A
Viruses; 2022 May; 14(5):. PubMed ID: 35632759
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
[TBL] [Abstract][Full Text] [Related]
16. Increasing efficiency of human mesenchymal stromal cell culture by optimization of microcarrier concentration and design of medium feed.
Chen AK; Chew YK; Tan HY; Reuveny S; Weng Oh SK
Cytotherapy; 2015 Feb; 17(2):163-73. PubMed ID: 25304664
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
Bioeng Bugs; 2010; 1(6):429-33. PubMed ID: 21468212
[TBL] [Abstract][Full Text] [Related]
18. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
Rourou S; van der Ark A; van der Velden T; Kallel H
Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
20. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor.
Rourou S; van der Ark A; Majoul S; Trabelsi K; van der Velden T; Kallel H
Appl Microbiol Biotechnol; 2009 Nov; 85(1):53-63. PubMed ID: 19521697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
